Sage Mountain Advisors LLC Acquires 153 Shares of Thermo Fisher Scientific Inc. $TMO

Sage Mountain Advisors LLC increased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.3% during the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,580 shares of the medical research company’s stock after purchasing an additional 153 shares during the period. Sage Mountain Advisors LLC’s holdings in Thermo Fisher Scientific were worth $1,046,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of TMO. Brighton Jones LLC boosted its stake in Thermo Fisher Scientific by 28.9% in the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock valued at $2,293,000 after acquiring an additional 988 shares in the last quarter. Revolve Wealth Partners LLC boosted its stake in Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after acquiring an additional 20 shares in the last quarter. GAMMA Investing LLC boosted its stake in Thermo Fisher Scientific by 22.0% in the first quarter. GAMMA Investing LLC now owns 4,862 shares of the medical research company’s stock valued at $2,419,000 after acquiring an additional 877 shares in the last quarter. Global Assets Advisory LLC acquired a new stake in Thermo Fisher Scientific in the first quarter valued at approximately $251,000. Finally, Spire Wealth Management boosted its stake in Thermo Fisher Scientific by 24.5% in the first quarter. Spire Wealth Management now owns 1,929 shares of the medical research company’s stock valued at $960,000 after acquiring an additional 379 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Stock Up 0.2%

TMO opened at $573.07 on Friday. The company has a fifty day moving average of $504.04 and a two-hundred day moving average of $453.30. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $610.97. The stock has a market capitalization of $216.40 billion, a price-to-earnings ratio of 33.11, a PEG ratio of 3.24 and a beta of 0.77. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.50 and a current ratio of 1.50.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.50 by $0.29. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The business had revenue of $11.12 billion for the quarter, compared to analyst estimates of $10.90 billion. During the same quarter last year, the business earned $5.28 earnings per share. The company’s revenue for the quarter was up 4.9% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Insider Transactions at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the transaction, the chief executive officer directly owned 115,174 shares in the company, valued at approximately $57,697,567.04. The trade was a 7.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CAO Joseph R. Holmes sold 385 shares of the business’s stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the transaction, the chief accounting officer owned 2,319 shares in the company, valued at $1,142,408.97. The trade was a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 29,666 shares of company stock worth $13,990,971 over the last 90 days. 0.33% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on TMO. HSBC restated a “hold” rating and issued a $510.00 target price on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Citigroup raised their target price on shares of Thermo Fisher Scientific from $500.00 to $580.00 and gave the company a “neutral” rating in a research note on Thursday. Robert W. Baird lifted their price objective on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an “outperform” rating in a research note on Thursday, July 24th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Thermo Fisher Scientific in a research report on Thursday. Finally, Raymond James Financial restated an “outperform” rating and issued a $535.00 target price (up previously from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Nineteen research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat.com, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and an average target price of $595.75.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.